Literature DB >> 25455354

The role of botulinum toxin in vasospastic disorders of the hand.

Michael W Neumeister1.   

Abstract

Raynaud phenomenon may be a primary disorder or associated with a variety of other autoimmune processes. Raynaud phenomenon produces digital vasospasm, which can lead to ischemia and ulceration. The treatment of Raynaud phenomenon has been difficult because multiple medical treatments have not provided uniform resolution of symptoms. Many patients have turned to surgery and sympathectomies for the treatment of unrelenting vasospasm. Botulinum toxin has been shown to be an effective alternative to surgery, with a single treatment being capable of resolving pain and healing ulcer. This article reviews the use of botulinum toxin for the treatment of Raynaud phenomenon.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Botox; Botulinum toxin; Ischemia; Pain; Raynaud; Vasodilation; Vasospasm

Mesh:

Substances:

Year:  2014        PMID: 25455354     DOI: 10.1016/j.hcl.2014.09.003

Source DB:  PubMed          Journal:  Hand Clin        ISSN: 0749-0712            Impact factor:   1.907


  8 in total

Review 1.  Evidence-based management of Raynaud's phenomenon.

Authors:  Ariane L Herrick
Journal:  Ther Adv Musculoskelet Dis       Date:  2017-11-20       Impact factor: 5.346

2.  Extended Periarterial Sympathectomy: Evaluation of Long-term Outcomes.

Authors:  Collier S Pace; Wyndell H Merritt
Journal:  Hand (N Y)       Date:  2017-06-23

3.  Management of vasopressor induced ischemia.

Authors:  Michael Livesey; Julio J Jauregui; Max C Hamaker; Raymond A Pensy; Christopher G Langhammer; W Andrew Eglseder
Journal:  J Orthop       Date:  2020-10-16

Review 4.  Raynaud's phenomenon.

Authors:  Ariane L Herrick
Journal:  J Scleroderma Relat Disord       Date:  2019-02-13

5.  Botulinum Toxin A for the Treatment of Sympathomimetic Pressor-Induced Digital Hand Ischemia in the Critically Ill Intensive Care Unit Patient.

Authors:  Henning De May; Avra S Laarakker; Gregory Borah
Journal:  Hand (N Y)       Date:  2022-02-21

Review 6.  Preclinical Evidence for the Role of Botulinum Neurotoxin A (BoNT/A) in the Treatment of Peripheral Nerve Injury.

Authors:  Michael Adler; Sabine Pellett; Shashi K Sharma; Frank J Lebeda; Zygmunt F Dembek; Mark A Mahan
Journal:  Microorganisms       Date:  2022-04-24

7.  Botulinum Toxin in the Treatment of Vasopressor-associated Symmetric Peripheral Gangrene.

Authors:  Jenna R Stoehr; Aaron M Kearney; Jonathan P Massie; Jason H Ko; Gregory A Dumanian
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-05-21

8.  Botulinum toxin type A in the treatment of Raynaud's phenomenon: A three-year follow-up study.

Authors:  Susana Medina; Alba Gómez-Zubiaur; Nuria Valdeolivas-Casillas; Isabel Polo-Rodríguez; Lucia Ruíz; Carmen Izquierdo; Cristina Guirado; Alicia Cabrera; Lidia Trasobares
Journal:  Eur J Rheumatol       Date:  2018-10-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.